$MNOV
MEDICINOVA INC

2017 Q2 Form 10-Q Financial Statement

#000156459017014096 Filed on July 26, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.910M $850.0K
YoY Change -14.73% -53.3%
% of Gross Profit
Research & Development $800.0K $590.0K
YoY Change -11.11% -35.16%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $2.805K $1.440K
YoY Change -12.48% -47.37%
Operating Profit -$2.805M
YoY Change -12.47%
Interest Expense $20.00K $20.00K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$10.00K -$30.00K
YoY Change 0.0% 200.0%
Pretax Income -$2.787M -$1.450M
YoY Change -12.87% -46.89%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.789K -$1.449K
YoY Change -12.82% -47.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$80.52K -$42.00K
COMMON SHARES
Basic Shares Outstanding 34.49M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.90M $24.10M
YoY Change -13.91% 9.05%
Cash & Equivalents $22.89M $24.12M
Short-Term Investments
Other Short-Term Assets $500.0K $600.0K
YoY Change -28.57% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $23.40M $24.70M
YoY Change -13.97% 8.69%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $100.0K
YoY Change 389.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $600.0K $600.0K
YoY Change 0.0% -14.29%
Other Assets
YoY Change
Total Long-Term Assets $15.10M $15.11M
YoY Change -0.66% -0.44%
TOTAL ASSETS
Total Short-Term Assets $23.40M $24.70M
Total Long-Term Assets $15.10M $15.11M
Total Assets $38.50M $39.81M
YoY Change -9.2% 5.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $367.3K
YoY Change 50.0% 115.05%
Accrued Expenses $1.100M $1.263M
YoY Change 0.0% -4.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.400M $1.630M
YoY Change 7.69% 9.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.700M $1.700M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $1.700M $1.700M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.400M $1.630M
Total Long-Term Liabilities $1.700M $1.700M
Total Liabilities $5.070M $5.281M
YoY Change 1.4% 2.48%
SHAREHOLDERS EQUITY
Retained Earnings -$336.1M -$330.3M
YoY Change 3.1% 3.4%
Common Stock $369.6M $364.9M
YoY Change 1072138.83% 1218049.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.39M $34.53M
YoY Change
Total Liabilities & Shareholders Equity $38.46M $39.81M
YoY Change -9.22% 5.03%

Cashflow Statement

Concept 2017 Q2 2016 Q4
OPERATING ACTIVITIES
Net Income -$2.789K -$1.449K
YoY Change -12.82% -47.02%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$1.410M -$1.060M
YoY Change -5.37% -29.8%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.660M 240.0K
YoY Change 504.55% -1300.0%
NET CHANGE
Cash From Operating Activities -1.410M -1.060M
Cash From Investing Activities 0.000 -10.00K
Cash From Financing Activities 2.660M 240.0K
Net Change In Cash 1.250M -830.0K
YoY Change -217.92% -45.75%
FREE CASH FLOW
Cash From Operating Activities -$1.410M -$1.060M
Capital Expenditures $0.00 -$10.00K
Free Cash Flow -$1.410M -$1.050M
YoY Change -4.73% -30.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
35019
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369544260
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-94785
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336098225
CY2017Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1956000
CY2017Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1694163
CY2017Q2 us-gaap Liabilities
Liabilities
5070054
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
33386269
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38456323
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35018640
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35018640
CY2017Q2 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
897208
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-96000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330293064
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
34531929
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39813134
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34523678
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34523678
CY2016Q2 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
962706
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1956000
CY2016Q4 us-gaap Liabilities
Liabilities
5281205
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
34525
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
364886468
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
2804988
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4030641
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4558305
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1694163
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
3204757
us-gaap Operating Expenses
OperatingExpenses
5828510
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2789138
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2804988
CY2017Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6027
CY2017Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
24408
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2786607
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-2788637
us-gaap Share Based Compensation
ShareBasedCompensation
1928039
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14454
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1673
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-117260
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-214784
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3958519
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33134
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-33134
mnov Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptionsAndWarrantsNetOfIssuanceCosts
2665225
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
65025
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2730250
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
279
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1227990
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22076749
us-gaap Income Taxes Paid
IncomeTaxesPaid
5080
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p></div>
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4432017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1160000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.96
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.01
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.46
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
mnov Stock Issuance Limit Under Employee Stock Purchase Plan Description
StockIssuanceLimitUnderEmployeeStockPurchasePlanDescription
shares reserved automatically increase each year by a number equal to the lesser of: (i) 15,000 shares; (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or (iii) such lesser amount as determined by the Board.
mnov Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
12775
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6456064
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6138951
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1800000
us-gaap License Costs
LicenseCosts
200000

Files In Submission

Name View Source Status
0001564590-17-014096-index-headers.html Edgar Link pending
0001564590-17-014096-index.html Edgar Link pending
0001564590-17-014096.txt Edgar Link pending
0001564590-17-014096-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mnov-10q_20170630.htm Edgar Link pending
mnov-20170630.xml Edgar Link completed
mnov-20170630.xsd Edgar Link pending
mnov-20170630_cal.xml Edgar Link unprocessable
mnov-20170630_def.xml Edgar Link unprocessable
mnov-20170630_lab.xml Edgar Link unprocessable
mnov-20170630_pre.xml Edgar Link unprocessable
mnov-ex101_306.htm Edgar Link pending
mnov-ex311_7.htm Edgar Link pending
mnov-ex312_9.htm Edgar Link pending
mnov-ex321_8.htm Edgar Link pending
mnov-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending